ReACp53靶向突变p53蛋白在去势抵抗性前列腺癌中的治疗潜力
本研究探讨细胞穿透肽ReACp53靶向突变p53蛋白聚集对去势抵抗性前列腺癌(CRPC)细胞的生物学效应。体外实验显示ReACp53可恢复p53转录功能、诱导线粒体细胞死亡并减少DNA合成,体内实验抑制异种移植瘤生长。结果提示靶向突变p53蛋白在晚期前列腺癌中具有治疗潜力。
要点
- ReACp53可靶向突变p53蛋白的淀粉样聚集并恢复其核转录功能。
- ReACp53诱导线粒体细胞死亡并减少突变p53前列腺癌细胞的DNA合成。
- ReACp53在体内抑制异种移植瘤生长,提示晚期前列腺癌治疗潜力。
核心结论
- 靶向突变p53蛋白在晚期前列腺癌中具有治疗潜力,可能改变该类肿瘤的管理方式。
研究设计与样本
- 采用免疫沉淀、免疫荧光、克隆存活、细胞增殖实验、流式细胞分析及体内异种移植模型研究ReACp53对携带突变p53的前列腺癌细胞的生物学效应。
主要发现
- ReACp53靶向突变p53蛋白的淀粉样聚集并恢复p53作为转录因子的核功能。
- ReACp53诱导线粒体细胞死亡并减少携带突变p53的前列腺癌细胞的DNA合成。
- ReACp53在体内抑制异种移植瘤生长。
临床怎么用
- 针对携带突变p53的晚期前列腺癌(尤其是去势抵抗性)可考虑靶向p53聚集的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS: p53 is a tumor suppressor that prevents cancer onset and progression, and mutations in the p53 gene cause loss of the tumor suppressor function of the protein. The mutant p53 protein in tumor cells can form aggregates which contribute to the dominant-negative effect over the wild-type p53 protein, causing loss of p53 tumor suppression or gain of novel oncogenic functions. Mutations in p53 have been implicated in the pathogenesis of primary prostate cancer (PCa), and are often detected in recurrent and metastatic disease. Thus, targeting mutant p53 may constitute an alternative therapeutic strategy for advanced PCa for which there are no other viable options. METHODS: In this study, we used immunoprecipitation, immunofluorescence, clonogenic survival, and cell proliferation assays, flow cytometric analysis and in vivo xenograft to investigate the biological effects of ReACp53, a cell-permeable peptide inhibitor of p53 aggregation, on mutant p53-carrying PCa cells. RESULTS: Our results show that ReACp53 targets amyloid aggregates of mutant p53 protein and restores the p53 nuclear function as transcriptional factor, induces mitochondrial cell death and reduces DNA synthesis of mutant p53-carrying PCa cells; ReACp53 also inhibits xenograft tumor growth in vivo. CONCLUSIONS: The data presented here suggest a therapeutic potential of targeting mutant p53 protein in advanced PCa setting, which has a clinical impact for aggressive PCa with transforming how such tumors are managed.
引用
- Zhang Y, Xu L, Chang Y, et al. Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. Prostate Cancer Prostatic Dis. 2019. PMID: 31471556. doi:10.1038/s41391-019-0172-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。